Abzena, a UK life sciences group providing services and technologies that enable the development and manufacture of biopharmaceutical products, has appointed Dr Campbell Bunce to the new role of Senior Vice President, Scientific Operations.
Bunce will join Abzena’s Executive Management Team, reporting to John Burt, CEO. He will have responsibility for the immunology and protein engineering groups and will work alongside Chief Scientific Officer, Matthew Baker, to provide immunology expertise to support internal research and partners’ projects. He will be based in Abzena’s Cambridge office.
He joins the firm from Oxford Immunotec where he was General Manager, Immunology Products, having previously worked at Immune Targeting Systems as R&D Director.